KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities.

Slides:

Advertisements

Similar presentations

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

Advertisements

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma Julien Faget, PhD, Caroline Contat, MS, Nadine.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

Molecular Predictors of Sensitivity to the MET Inhibitor PHA in Lung Carcinoma Cells Daisuke Matsubara, MD, PhD, Shumpei Ishikawa, MD, PhD, Sachiko.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

CHK1 downregulation upon ERG overexpression.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

DAB2IP expression is selectively lost in luminal B breast cancers and it functions as a tumor suppressor by affecting multiple RAS isoforms. DAB2IP expression.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Endogenously presented LNP is recognized by KIR2DS2 in the context of HCV. Endogenously presented LNP is recognized by KIR2DS2 in the context of HCV. (A)

BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. BRAFV600E promotes glycolysis in melanoma cells via regulation.

Changes in mRNA levels do not correlate with changes in protein levels in upf1Δ and xrn1Δ cells. Changes in mRNA levels do not correlate with changes in.

CHGB conducts F− and Cl− better than other anions.

Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells Wan Seok Yang,

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.

Induction of Leptin Resistance by Activation of cAMP-Epac Signaling

Volume 42, Issue 1, Pages (April 2011)

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

Endogenously presented LNP is recognized by KIR2DS2 in the context of HCV. Endogenously presented LNP is recognized by KIR2DS2 in the context of HCV. (A)

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

Arginine-to-lysine mutations conferring TRIM22 restriction and lysine-to-arginine mutations causing loss of TRIM22 restriction. Arginine-to-lysine mutations.

(A) Western blot probing nuclear extract from wild-type (wt) and the newly generated ACF1 mutant (AcfC) embryos (0–16 h). (A) Western blot probing nuclear.

ABT-199 efficiently kills primary AML myeloblasts as a single agent.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

BCR–ABL kinase activity rewires GM-CSFR signaling and confers oncogene addiction in TF1 cells. BCR–ABL kinase activity rewires GM-CSFR signaling and confers.

Inhibition of lung cancer cell proliferation and viability by CYT387.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

The role of p53 in H2O2-mediated cell death of hOGG1-deficient H1299 lung carcinoma p53 null cells. The role of p53 in H2O2-mediated cell death of hOGG1-deficient.

A, PTEN loss signature score in resected SQCLC brain metastases.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Integrated mRNA and microRNA expression and DNA methylation clusters.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

TSA-mediated changes in cell cycle inhibitor proteins.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

Effect of G9a on the expression of GSH synthesis enzymes.

Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.

HNSCC and NSCLC cell lines display differential sensitivities to cixutumumab in the 3D mimic condition. HNSCC and NSCLC cell lines display differential.

Targeting DCLK1 by miRNA-137.

Initial testing and characterization of cAMPr in ES cells.

Changes in signal transduction pathway induced by gefitinib.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Tivantinib does not inhibit MET function.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Stk11/Lkb1 ablation directly promotes primary resistance to PD-L1/PD-1 blockade in immunocompetent murine models of Kras-mutant LUAC. Stk11/Lkb1-proficient/deficient.

Transcriptional activity and growth of mutant ER in a breast cancer cell line. Transcriptional activity and growth of mutant ER in a breast cancer cell.

Wnt5A decreases ROR1 expression through proteasomal degradation.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Tumor-suppressor Lkb1 inactivation promotes neutrophil accumulation via proinflammatory cytokines and chemokines. Tumor-suppressor Lkb1 inactivation promotes.

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.

BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. BRAF-mutant melanoma cells are resistant to the antigrowth.

KRAS-mutant lung adenocarcinoma subsets exhibit distinct patterns of immune system engagement. KRAS-mutant lung adenocarcinoma subsets exhibit distinct.

G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

EZH2-driven lung cancer as a molecularly distinct entity.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

Inhibition of HDACs disrupts DNMT1 association with Hsp90.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

KRAS co-mutations are associated with distinct therapeutic vulnerabilities. KRAS co-mutations are associated with distinct therapeutic vulnerabilities. A, reanalysis of drug sensitivity data (34) for 19 KRAS-mutant NSCLC cell lines based on the presence of co-mutations in STK11/LKB1 and TP53. KRAS;LKB1 (KLm) and KRAS;TP53;LKB1 (KPLm) triple-mutant lines were grouped together (n = 9) for this analysis and compared with KRAS;TP53 (KPm) lines with wild-type STK11/LKB1 status (n = 10). Drugs with Wilcoxon rank-sum test–derived P values ≤ 0.1 for the (KLm+KPLm) versus KPm comparison are displayed, and fold change in mean IC50 values is plotted on the x axis. Asterisk denotes statistical significance at the P ≤ 0.05 level. B, KRAS-mutant NSCLC cell lines with LKB1 inactivation show increased sensitivity to HSP90 inhibition. Scatter plots of median IC50 values (nmol/L; from three to five independent experiments) of 10 KLm/KPLm and 12 KPm cell lines for three chemically distinct HSP90 inhibitors. The Wilcoxon rank-sum test is used for statistical comparison. C, Western blot analysis of LKB1 expression in three isogenic pairs of LKB1-deficient/proficient KRAS-mutant NSCLC cell lines. D, LKB1 status–dependent sensitization of KRAS-mutant NSCLC cell lines to HSP90 inhibitors. Log10IC50 (nmol/L) values from five to six independent experiments for each isogenic pair were compared using the unpaired t test. *, significance at the P ≤ 0.05 level; **, significance at the P ≤ 0.01 level. Error bars, SD of the mean. E, ganetespib (GAN) simultaneously destabilizes multiple proteins that support the fitness of KRAS-mutant NSCLC cell lines with LKB1 inactivation. DMSO, dimethyl sulfoxide. F, NQO1-mediated bioactivation contributes to the sensitivity of NSCLC cell lines to 17-AAG. Top, robust expression of NQO1 among KRAS;(TP53);LKB1 lines, which frequently harbor co-occurring mutations in KEAP1[K(P)LKm]. KP lines display variable NQO1 expression (CALU-6 expresses NQO1 after prolonged exposure). The *2NQO1- polymorphic H596 cell line is used as negative control. Bottom, cotreatment with dicumarol, an NQO1-inhibitor, renders KRAS-mutant NSCLC partially resistant to 17-AAG. Unpaired t test is used for all statistical comparisons. Error bars, SD of the mean from two independent experiments. G, differential expression of NQO1 mRNA in the three KRAS-mutant lung adenocarcinoma subgroups in the TCGA (left) and PROSPECT (right) cohorts. ANOVA is used for statistical comparison. Ferdinandos Skoulidis et al. Cancer Discovery 2015;5:860-877 ©2015 by American Association for Cancer Research